GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » 50-Day SMA

Cleo Diagnostics (ASX:COV) 50-Day SMA : A$0.19 (As of May. 11, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-05-11), Cleo Diagnostics's 50-Day SMA is A$0.19. It's 20-Day SMA is A$0.18 and 200-Day SMA is A$N/A.


Competitive Comparison of Cleo Diagnostics's 50-Day SMA

For the Medical Devices subindustry, Cleo Diagnostics's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cleo Diagnostics's 50-Day SMA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's 50-Day SMA falls into.



Cleo Diagnostics  (ASX:COV) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cleo Diagnostics  (ASX:COV) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Cleo Diagnostics 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleo Diagnostics (ASX:COV) Business Description

Traded in Other Exchanges
N/A
Address
480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines